Physician
Agoston Gyula Szabo
Department of Medical Diseases, Vejle Hospital
| Projekt styring | ||
| Projekt status | Active | |
| Data indsamlingsdatoer | ||
| Start | 01.06.2017 | |
| Slut | 31.05.2018 | |
A retrospective study of the treatment of patients with multiple myeloma diagnosed between 2006 and 2017 at Vejle Hospital
Short summary
Multiple myeloma is an incurable cancer can result in symptoms such as anemia, bone lesions, bone pain, renal failure, hypercalcemia and susceptibility to infections. The available treatment options have evolved greatly in the last two decades. However, the treatment of relapsed or refractory disease is challenging and local treatment practices differ. This study describes retrospective real-life data from a community hospital with wide availability of clinical trials, extensive use of novel agents and use of certain forms of supportive therapy.
Rationale
Results from international multicenter reviews suggest that the treatment of relapsed or refractory multiple myeloma is challenging. After the first two-three lines of therapy the majority of patients does not respond to the next treatment. Moreover, the number of patients who are offered treatment decreases significantly per each additional line of therapy. This study describes retrospective real-life data from a community hospital with wide availability of clinical trials, extensive use of novel agents and use of certain forms of supportive therapy.
Description of the cohort
Patient diagnosed with multiple myeloma between 1.1.2006 and 1.1.2017.
Data and biological material
Patient records, peripheral blood tests, pathology reports, treatment schemes and imaging reports will be reviewed.